202 related articles for article (PubMed ID: 2182519)
1. Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
Topalian SL; Rosenberg SA
Important Adv Oncol; 1990; ():19-41. PubMed ID: 2182519
[No Abstract] [Full Text] [Related]
2. Natural killer cells and tumor immunity: 1987.
Hiserodt JC; Herberman RB
Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
[No Abstract] [Full Text] [Related]
3. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
Whiteside TL; Heo DS; Takagi S; Herberman RB
Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
[No Abstract] [Full Text] [Related]
4. Natural killer cells and tumor immunity: 1985.
Herberman RB
Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
[No Abstract] [Full Text] [Related]
5. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
[No Abstract] [Full Text] [Related]
6. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Spiess PJ; Yang JC; Rosenberg SA
J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
[TBL] [Abstract][Full Text] [Related]
7. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
Miescher S; Whiteside TL; Moretta L; von Fliedner V
J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
[TBL] [Abstract][Full Text] [Related]
8. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
9. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
11. Human interleukin 2: molecular biology, physiology and clinical possibilities.
Mertelsmann R; Welte K
Immunobiology; 1986 Sep; 172(3-5):400-19. PubMed ID: 3100434
[No Abstract] [Full Text] [Related]
12. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.
Forni G; Giovarelli M; Santoni A; Modesti A; Forni M
J Immunol; 1987 Jun; 138(11):4033-41. PubMed ID: 2953796
[TBL] [Abstract][Full Text] [Related]
13. Clonogenic and functional potential of T lymphocytes infiltrating human solid tumors.
von Fliedner V; Qiao L; Whiteside TL; Leyvraz S; Barras C; Miescher S
Prog Clin Biol Res; 1987; 244():223-32. PubMed ID: 3498950
[No Abstract] [Full Text] [Related]
14. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
15. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
[No Abstract] [Full Text] [Related]
16. Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest.
Lafreniere R; Borkenhagen K; Bryant LD; Ng E
J Biol Response Mod; 1989 Jun; 8(3):238-51. PubMed ID: 2787392
[TBL] [Abstract][Full Text] [Related]
17. Contrasuppression, tolerance, and tumor immunity.
Green DR; Friedman A; Ptak W; McGhee J; Flood PM
Prog Clin Biol Res; 1989; 288():245-58. PubMed ID: 2566175
[No Abstract] [Full Text] [Related]
18. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
20. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
